The use of artificial intelligence (AI) in drug development has been hyped up for some time now – and the COVID-19 pandemic is finally a chance for these technologies to prove their worth.
It's official - Gilead's remdesivir helps severely ill patients recover faster from COVID-19, according to results from a phase 3 placebo-controlled trial.
